Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism.
Mansour
Jeannette
J
Shahapuni
Irina
I
Mailliez
Sébastien
S
Aghai
Rachid
R
Fournier
Albert
A
D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004872:Ergocalciferols / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000037:antagonists & inhibitors / Q000097:blood*; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents; D004872:Ergocalciferols; D010281:Parathyroid Hormone; C084656:paricalcitol